JP2021523931A5 - - Google Patents

Info

Publication number
JP2021523931A5
JP2021523931A5 JP2021500503A JP2021500503A JP2021523931A5 JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5 JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
eudragit
formulation according
mc1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023575 external-priority patent/WO2019183472A1/en
Publication of JP2021523931A publication Critical patent/JP2021523931A/ja
Publication of JP2021523931A5 publication Critical patent/JP2021523931A5/ja
Pending legal-status Critical Current

Links

JP2021500503A 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法 Pending JP2021523931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
US62/647,000 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (2)

Publication Number Publication Date
JP2021523931A JP2021523931A (ja) 2021-09-09
JP2021523931A5 true JP2021523931A5 (https=) 2022-03-28

Family

ID=67988087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500503A Pending JP2021523931A (ja) 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法

Country Status (13)

Country Link
US (1) US20220088146A1 (https=)
EP (1) EP3768245A4 (https=)
JP (1) JP2021523931A (https=)
KR (1) KR102743821B1 (https=)
CN (1) CN112188888A (https=)
AU (2) AU2019239300A1 (https=)
BR (1) BR112020019128A2 (https=)
CA (1) CA3095036A1 (https=)
EA (1) EA202092275A1 (https=)
IL (1) IL277496B2 (https=)
MX (1) MX2020009900A (https=)
PH (1) PH12020551596A1 (https=)
WO (1) WO2019183472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515617A (zh) * 2020-02-03 2022-12-23 帕拉丁科技公司 二胺连接的受体特异性环状肽
JPWO2024143501A1 (https=) * 2022-12-28 2024-07-04

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2440572B1 (en) * 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
JP5999702B2 (ja) * 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
EP3187171B1 (en) * 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20150306230A1 (en) * 2014-04-28 2015-10-29 Celanese Acetate Llc Drug delivery vehicles comprising cellulose derivatives, starch derivatives, and combinations thereof
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Similar Documents

Publication Publication Date Title
ES2241603T3 (es) Formulacion oral para la administracion al ileon que comprende un compuesto inhibidor del transporte de acidos biliares presentes en el ileon.
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
JP3806740B2 (ja) 薬剤運搬組成物
ES2645930T3 (es) Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
JP3725542B2 (ja) ピコサルフェート剤形
AU2002226955B2 (en) Pharmaceutical dosage form with multiple coatings
JP2009523175A5 (https=)
MXPA04003367A (es) Formulacion oral microparticulada galenica para la liberacion retrasada y controlada de principios activos farmaceuticos.
JP3633936B2 (ja) センナ剤形
JP2022514569A (ja) 非晶質スパルセンタン組成物
JP2004507487A (ja) 腸疾患治療薬
JP2021523931A5 (https=)
JP5778184B2 (ja) 上皮増殖因子の経口投与可能薬学的ペレット
WO2013169925A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2019513801A5 (https=)
CN105919979B (zh) 一种替曲朵辛肠溶缓释微丸、制备方法及其应用
CN105434398B (zh) 一种雷贝拉唑肠溶微丸及其制备方法
WO2002004016A1 (fr) Preparations enteriques contenant des peptides physiologiquement actifs
KR20240125702A (ko) 중수소화 돔페리돈 조성물, 방법, 및 제조
CN102133346A (zh) 一种含有川芎和天麻的脉冲释放口服药物制剂
WO2007010930A1 (ja) 口腔内崩壊製剤用の薬物含有被覆微粒子及びその製造方法
JP2019515045A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法